The Japan Patent Office has granted a patent which protects the system design of MaMa-K, a solution that reduces radiation of healthy tissue during radiation treatment. With this approval, Kongsberg Beam Technology has further strengthened the intellectual property of the MaMa-K.
“We’re thrilled that the overall concept of MaMa-K has been approved in Japan which will enable us to secure the very important Asian market. The patent has earlier been granted in the US, Sweden, Australia and Europe, and we have filed for more patent approvals around the world. More cancer patients will now benefit from personalised radiation treatment, saving healthy tissue from damage and reducing side effects”, says CEO Kerstin Jakobsson.
For further information, please contact:
CEO, Kongsberg Beam Technology AS
Phone: +46 705 50 45 40
About Kongsberg Beam Technology
Kongsberg Beam Technology is a MedTech company preventing radiation of healthy tissue in oncology applications by the innovative solution, MaMa-K™ which is applicable both in traditional radiation therapy and proton therapy. The technology of MaMa-K is based on a digital twin of the patient with motion tracking in real-time to create a more efficient radiation treatment with less damage of healthy tissue. Kongsberg Beam Technology is headquartered in Kongsberg, Norway. For more information, please visit www.kongsbergbeamtech.com.